Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595322 · ClinicalTrials.gov registry record · NA
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00595322: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00595322 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00595322, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted. This study will also give us some information about whether the combination of Bevacizumab and radiation has potential to become an effective treatment for regrowing brain tumors. Bevacizumab is an experimental drug that blocks a molecule called VEGF that is found in high amounts in malignant gliomas. VEGF promotes the growth of blood vessels that bring nutrients to tumor cells. In studies with laboratory animals, Bevacizumab slowed the growth of several different types of human cancer cells by blocking the effects of VEGF. There is also evidence that Bevacizumab enhances the effects of radiation on tumor cell
Interventions
- OTHER bevacizumab and radiation (IMRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-12 |
| Est. Completion | 2017-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595322
The ClinicalTrials.gov registry entry for NCT00595322 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevacizumab and radiation (IMRT) is the first listed.
NCT00595322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00595322 about?
NCT00595322 is a clinical study titled "Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma". This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted. This study will also give us some information about whether the combination of Bevacizumab and radiation has potential to become an effec...
What is the current status of trial NCT00595322?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2005-12. Estimated completion is 2017-05.
What interventions are being tested in trial NCT00595322?
The interventions under investigation include: bevacizumab and radiation (IMRT) (OTHER).
Who is sponsoring clinical trial NCT00595322?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.